BMC Medicine (Nov 2024)

Diastolic dysfunction and risks of heart failure and death in long-term adult cancer survivors

  • Rongjian Yu,
  • Juze Lin,
  • Tingting Fu,
  • Xuhui Huang,
  • Fei Xu,
  • Caizhi Yang,
  • Yuanfeng Fu,
  • Hongwen Fei,
  • Lizhu Lin

DOI
https://doi.org/10.1186/s12916-024-03773-6
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background Cancer survivors face elevated risks of heart failure (HF) and death, with cardiac dysfunction being a significant concern. Current evaluations often emphasize systolic function while insufficiently addressing diastolic function. This study aims to investigate the prevalence of diastolic dysfunction and assess its prognostic implications in long-term cancer survivors. Methods We analyzed participants from the Atherosclerosis Risk in Communities (ARIC) Study with complete echocardiographic assessments and documented cancer histories. Diastolic function was classified by guideline criteria: normal (≤ 1 abnormal parameter), indeterminate (2 abnormal parameters), and dysfunction (≥ 3 abnormal parameters). The primary outcomes were incident HF and all-cause death. Diastolic dysfunction prevalence was compared between cancer survivors and non-cancer participants after propensity score matching. Cox regression, Kaplan–Meier, and restricted cubic spline (RCS) analyses were used to assess associated risks. Results A total of 5322 participants were included, with 18.4% (N = 979) being cancer survivors. The mean age of cancer survivors at echocardiography was 76.3 (5.10) years, with a median of 12.17 years since diagnosis. There were no significant differences in diastolic dysfunction prevalence (12.26% vs 10.73%, P = 0.29) after matching. Cox regression revealed a graded association between diastolic dysfunction and risks of HF and death. Fully adjusted hazard ratios were 2.59 (95% CI: 1.59–4.20, P < 0.001) for indeterminate diastolic function and 4.41 (95% CI: 2.40–8.12, P < 0.001) for diastolic dysfunction in HF; and 1.68 (95% CI: 1.26–2.25, P < 0.001) for indeterminate and 2.21 (95% CI: 1.51–3.22, P < 0.001) for diastolic dysfunction in all-cause death. These results were consistent across subgroup and sensitivity analyses and supported by Kaplan–Meier curves. RCS analyses demonstrated dose–response relationships between individual diastolic parameters and outcomes. Conclusions Diastolic dysfunction is prevalent among long-term cancer survivors and is stepwise associated with adverse outcomes. These findings underscore the essential need for ongoing monitoring of diastolic function in this population.

Keywords